Structured reporting for magnetic resonance imaging of the prostate using PI-RADS 2.1

Andreas Hötker, Olivio F. Donati

Article ID: 1751
Vol 5, Issue 2, 2022

VIEWS - 533 (Abstract) 217 (PDF)

Abstract


Clinical/methodological problem: The identification of clinically significant prostate carcinomas while avoiding overdiagnosis of low-malignant tumors is a challenge in routine clinical practice. Standard radiologic procedures: Multiparametric magnetic resonance imaging (MRI) of the prostate acquired and interpreted according to PI-RADS (Prostate Imaging Reporting and Data System Guidelines) is accepted as a clinical standard among urologists and radiologists. Methodological innovations: The PI-RADS guidelines have been newly updated to version 2.1 and, in addition to more precise technical requirements, include individual changes in lesion assessment. Performance: The PI-RADS guidelines have become crucial in the standardization of multiparametric MRI of the prostate and provide templates for structured reporting, facilitating communication with the referring physician. Evaluation: The guidelines, now updated to version 2.1, represent a refinement of the widely used version 2.0. Many aspects of reporting have been clarified, but some previously known limitations remain and require further improvement of the guidelines in future versions.


Keywords


Prostate Carcinoma; Multiparametric Magnetic Resonance Imaging; Prostate Aspecific Antigen; Transitional Zone; Scoring System

Full Text:

PDF


References


1. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. European Radiology 2012; 22(4): 746–757.

2. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging-Reporting and data system: 2015, version 2. European Urology 2016; 69(1): 16–40.

3. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. European Urology 2019; 76(3): 340–351.

4. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet 2017; 389(10071): 815–822.

5. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate cancer diagnosis. The New England Journal of Medicine 2018; 378(19): 1767–1777.

6. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313(4): 390–397.

7. AWMF. S3-Leitlinie Prostatakarzinom [Internet]. Version 6.0. 2021 [cited 2021 Jun 17]. Available from: https://www.leitlinienprogramm-onkologie. de/leitlinien/prostatakarzinom/.

8. Bjurlin MA, Carroll PR, Eggener S, et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. The Journal of Urology 2020; 203(4): 706–712.

9. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. European Urology 2017; 71(4): 618–629.

10. Vargas HA, Hötker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: Critical evaluation using whole-mount pathology as standard of reference. Euopean Radiology 2016; 26(6): 1606–1612.

11. Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. European Urology 2019; 75(3): 385–396.

12. Franiel T, Röthke M. Prostatadiagnostik nach PI-RADS 2.0 (German) [Prostate diagnostics according to PI-RADS 2.0]. Radiologist 2017; 57(8): 665–678.

13. Schlemmer HP. Multiparametrische MRT der Prostata (German) [Multiparametric MRI of the prostate]. Radiologist 2017; 57(8): 621–630.

14. Schwartz LH, Panicek DM, Berk AR, et al. Improving communication of diagnostic radiology findings through structured reporting. Radiology 2011; 260(1): 174–181.

15. Wetterauer C, Winkel DJ, Federer-Gsponer JR, et al. Structured reporting of prostate magnetic resonance imaging has the potential to improve interdisciplinary communication. PLoS One 2019; 14(2): e212444.

16. Bhayana R, O’Shea A, Anderson MA, et al. PI-RADS versions 2 and 2.1: Interobserver agreement and diagnostic performance in peripheral and transition zone lesions among six radiologists. American Journal of Roentgenology 2021; 217: 141–151.

17. Byun J, Park KJ, Kim M-H, et al. Direct comparison of PI-RADS version 2 and 2.1 in transition zone lesions for detection of prostate cancer: Preliminary experience. Journal of Magnetic Resonance Imaging 2020; 52(2): 577–586.

18. Lim CS, Abreu-Gomez J, Carrion I, et al. Prevalence of prostate cancer in PI-RADS version 2.1 transition zone atypical nodules upgraded by abnormal DWI: Correlation with MRI-directed TRUS-guided targeted biopsy. American Journal of Roentgenology 2021; 216: 683–690.

19. Tamada T, Kido A, Takeuchi M, et al. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. European Journal of Radiology 2019; 121: 108704.

20. Wang Z, Zhao W, Shen J, et al. PI-RADS version 2.1 scoring system is superior in detecting transition zone prostate cancer: A diagnostic study. Abdominal Radiology 2020; 45(12): 4142–4149.

21. Xu L, Zhang G, Zhang D, et al. Comparison of PI-RADS version 2.1 and PI-RADS version 2 regarding interreader variability and diagnostic accuracy for transition zone prostate cancer. Abdominal Radiology 2020; 45(12): 4133–4141.

22. Costa DN, Jia L, Subramanian N, et al. Prospectively PI-RADS v2.1 atypical benign prostatic hyperplasia nodules with marked restricted diffusion: Detection of Clinically significant prostate cancer on multiparametric MRI. American Journal of Roentgenology 2020; 217: 395–403.

23. Hötker AM, Blüthgen C, Rupp NJ, et al. Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement. PLoS One 2020; 15(10): e239975.

24. Linhares Moreira AS, De Visschere P, Van Praet C, et al. How does PI-RADS v2.1 impact patient classification? Ahead-to-head comparison between PI-RADS v2.0 and v2.1. Acta Radiologica 2020; 62(6).

25. Rudolph MM, Baur ADJ, Cash H, et al. Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer. Scientific Reports 2020; 10(1): 15982.

26. Ghafoor S, Becker AS, Woo S, et al. Comparison of PI-RADS versions 2.0 and 2.1 for MRI-based calculation of the prostate volume. Academic Radiology 2020; 28: 1548–1556.

27. Luis R, Leandro B, GonzaloV, et al. PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? Urolologic Oncology 2020; 39: 431.e9–431.e13.

28. Roscigno M, Stabile A, Lughezzani G, et al. The use of multiparametric magnetic resonance imaging for follow-up of patients included in active surveillance protocol. Can PSA density discriminate patients at different risk of reclassification? Clinical Genitourinary Cancer 2020; 18(6): e698–e704.

29. Distler FA, Radtke JP, Bonekamp D, et al. The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction. The Journal of Urology 2017; 198(3): 575–582.

30. Padhani AR, Barentsz J, Villeirs G, et al. PI-RADS steering committee: The PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 2019; 292(2): 464–474.

31. Donati OF, Chong D, Nanz D, et al. Diffusion-weighted MR imaging of upper abdominal organs: Field strength and intervendor variability of apparent diffusion coefficients. Radiology 2014; 270(2): 454–463.

32. Shukla-Dave A, Obuchowski NA, Chenevert TL, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. Journal of Magnetic Resonance Imaging 2019; 49(7): e101–e121.

33. Rosenkrantz AB, Babb JS, Taneja SS, et al. Proposed adjustments to PI-RADS version 2 decision rules: Impact on prostate cancer detection. Radiology 2017; 283(1): 119–129.

34. Moore CM, Giganti F, Albertsen P, et al. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: The PRECISE recommendations-A report of a European school of oncology task force. European Urology 2017; 71(4): 648–655.

35. Panebianco V, Villeirs G, Weinreb JC, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): International consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. European Urology Oncology 2021; 4(6): 868–876.

36. Giganti F, Allen C, Emberton M, et al. Prostate imaging quality (PI-QUAL): A new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. European Urology Oncology 2020; 3(5): 615–619.

37. HötkerAM, DappaE, Mazaheri Y, et al. The influence of background signal intensity changes on cancer detection in prostate MRI. American Journal of Roentgenology 2019; 212(4): 823–829.




DOI: https://doi.org/10.24294/irr.v5i2.1751

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.